https://padlet.com/puebljo/hqgh20auy3ot678t Infusion Protocol en-us 2021-10-18 00:35:52 UTC 2025-12-07 10:12:20 UTC hello@padlet.com puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822719341 Patients 12 years and older and weighs >=40 kg

Vaccinated or unvaccinated covid positive patients

No more than 10 days of symptom onset

]]> 2021-10-18 00:44:13 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822719341 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822719552 Manufactured antibodies bind to spike protein on viral surface

Antibodies prevent Covid virus from attaching and replicating

Has emergency use authorization (EUA) from the FDA

Not fully approved by the FDA]]> 2021-10-18 00:44:20 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822719552 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822723931 Older adults (65 years and older)

Pregnant women

Co-morbidities:
Asthma
CHF
CKD
CLD
DM
Obesity (BMI >=25 or greater than 85th percentile in PEDS)]]> 2021-10-18 00:46:51 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822723931 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822727804 CRM and pulse ox

Infusion time: About 20 mins. RN must stay with the patient at duration of treatment.

Full set of vital signs pre-infusion, start, q 15 mins, end, and post-infusion

20G IV or larger, given by itself

Use a pump and choose medication from drug library. Do not infuse wide-open.

Monitor patient for 30 minutes post-infusion.

Full set of vital signs within 30 minutes prior to patient discharge.]]> 2021-10-18 00:48:58 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822727804 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822733024 Most common side effects: nausea, vomiting, dizziness, hypotension, palpitations, tachycardia

Signs of allergic reaction: STOP infusion]]> 2021-10-18 00:51:45 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822733024 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822761033 MAB not authorized for use in patients requiring increased O2 therapy and increased O2 flow rate

Casirivimab and Indevimab (most common MABs used) - can produce worsening outcomes in patients requiring High Flow or mechanical ventilation]]> 2021-10-18 01:05:20 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822761033 puebljo https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822823591 Casirivimab 600 mg and Imdevimab 600 mg and given as a single infusion

Bamlanivimab 2,800 mg and Etesevimab 2,800 mg and given as a single infusion

Choice of drug is facility-dependent.]]> 2021-10-18 01:32:52 UTC https://padlet.com/puebljo/hqgh20auy3ot678t/wish/1822823591